{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:26:43Z","timestamp":1792427203534,"version":"4.5.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Relapse is common in major depressive disorder (MDD). In this study, we evaluated the incremental health care burden of relapse in patients with MDD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This real-world retrospective cohort study used administrative medical and pharmacy claims data to identify commercially insured adult patients in the United States diagnosed with MDD who initiated a new antidepressant between January 1, 2012, and September 30, 2017. All-cause health care resource utilization, total costs, and medication adherence were evaluated in two cohorts: patients with and patients without relapse. Relapse was defined as suicide attempts, psychiatric hospitalization, mental health\u2013related emergency department (ED) visit, use of electroconvulsive therapy, or reinitiation of treatment after a gap \u22656\u2009months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The study population included 14,186 patients (7093 baseline-matched patients per cohort). The mean follow-up period was 27.5 and 26.0\u2009months for patients with and patients without relapse, respectively. Patients with relapse had significantly higher rates of hospitalization (16.6% vs 8.5%;\n                      <jats:italic>p\u00a0&lt;<\/jats:italic>\n                      \u00a0.0001) and ED visits (54.8% vs 34.7%;\n                      <jats:italic>p\u00a0&lt;<\/jats:italic>\n                      \u00a0.0001) than patients without relapse. The total costs for patients with relapse were significantly higher ($12,594 vs $10,445;\u00a0\n                      <jats:italic>p\u00a0&lt;<\/jats:italic>\n                      \u00a0.0001). Patients with relapse were also less adherent to antidepressants (mean proportion of days covered, 0.43 vs 0.49;\n                      <jats:italic>p\u00a0&lt;<\/jats:italic>\n                      \u00a0.0001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Relapse of MDD was associated with increased total costs and health care utilization and lower adherence to antidepressants. Reducing the risk of relapse may result in a reduction of the associated health care burden; however, findings may only be generalizable to patients with commercial insurance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12888-022-03793-7","type":"journal-article","created":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T04:02:33Z","timestamp":1646107353000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Incremental burden of relapse in patients with major depressive disorder: a real-world, retrospective cohort study using claims data"],"prefix":"10.1186","volume":"22","author":[{"given":"Ma\u00eblys","family":"Touya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra F.","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Kangethe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lambros","family":"Chrones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Themmi","family":"Evangelatos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Polson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,1]]},"reference":[{"key":"3793_CR1","unstructured":"National Institute of Mental Health. Mental health information: statistics: major depression. 2019. https:\/\/www.nimh.nih.gov\/health\/statistics\/major-depression.shtml. Accessed December 16, 2020."},{"key":"3793_CR2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.4088\/JCP.14m09298","volume":"76","author":"PE Greenberg","year":"2015","unstructured":"Greenberg PE, Fournier A-A, Sisitsky T, Pike CT, Kessler RC. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry. 2015;76:155\u201362.","journal-title":"J Clin Psychiatry"},{"key":"3793_CR3","unstructured":"Gelenberg AJ, Freeman MP, Markowitz JC, Rosenbaum JF, Thase ME, Trivedi MH, et al. Practice guideline for the treatment of patients with major depressive disorder. 3rd\u00a0ed.\u00a0American Psychiatric Association\u00a0Published online October\u00a02010. https:\/\/psychiatryonline.org\/pb\/assets\/raw\/sitewide\/practice_guidelines\/guidelines\/mdd.pdf. Accessed December 16, 2020."},{"key":"3793_CR4","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.jad.2019.11.105","volume":"265","author":"AS Moriarty","year":"2019","unstructured":"Moriarty AS, Coventry PA, Hudson JL, Cook N, Fenton OJ, Bower P, et al. The role of relapse prevention for depression in collaborative care: a systematic review. J Affect Disord. 2019;265:618\u201344.","journal-title":"J Affect Disord"},{"key":"3793_CR5","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.cpr.2007.02.005","volume":"27","author":"SL Burcusa","year":"2007","unstructured":"Burcusa SL, Iacono WG. Risk for recurrence in depression. Clin Psychol Rev. 2007;27:959\u201385.","journal-title":"Clin Psychol Rev"},{"key":"3793_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ijnp\/pyv076","volume":"19","author":"K Sim","year":"2016","unstructured":"Sim K, Lau WK, Sim J, Sum MY, Baldessarini RJ. Prevention of relapse and recurrence in adults with major depressive disorder: systematic review and meta-analyses of controlled trials. Int J Neuropsychopharmacol. 2016;19:1\u201313.","journal-title":"Int J Neuropsychopharmacol"},{"key":"3793_CR7","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1176\/appi.ajp.157.2.229","volume":"157","author":"DA Solomon","year":"2000","unstructured":"Solomon DA, Keller MB, Leon AC, Mueller TI, Lavori PW, Shea MT, et al. Multiple recurrences of major depressive disorder. Am J Psychiatry. 2000;157:229\u201333.","journal-title":"Am J Psychiatry"},{"key":"3793_CR8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.cpr.2018.07.005","volume":"64","author":"JEJ Buckman","year":"2018","unstructured":"Buckman JEJ, Underwood A, Clarke K, Saunders R, Hollon SD, Fearon P, et al. Risk factors for relapse and recurrence of depression in adults and how they operate: a four-phase systematic review and meta-synthesis. Clin Psychol Rev. 2018;64:13\u201338.","journal-title":"Clin Psychol Rev"},{"key":"3793_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jad.2015.12.029","volume":"193","author":"SC Ho","year":"2016","unstructured":"Ho SC, Chong HY, Chaiyakunapruk N, Tangiisuran B, Jacob SA. Clinical and economic impact of non-adherence to antidepressants in major depressive disorder: a systematic review. J Affect Disord. 2016;193:1\u201310.","journal-title":"J Affect Disord"},{"key":"3793_CR10","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s40263-017-0417-0","volume":"31","author":"KR Keyloun","year":"2017","unstructured":"Keyloun KR, Hansen RN, Hepp Z, Gillard P, Thase ME, Devine EB. Adherence and persistence across antidepressant therapeutic classes: a retrospective claims analysis among insured US patients with major depressive disorder (MDD). CNS Drugs. 2017;31:421\u201332.","journal-title":"CNS Drugs"},{"key":"3793_CR11","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1001\/archpsyc.55.12.1128","volume":"55","author":"CA Melfi","year":"1998","unstructured":"Melfi CA, Chawla AJ, Croghan TW, Hanna MP, Kennedy S, Sredl K. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry. 1998;55:1128\u201332.","journal-title":"Arch Gen Psychiatry"},{"key":"3793_CR12","first-page":"63","volume":"3","author":"X Liu","year":"2011","unstructured":"Liu X, Chen Y, Faries DE. Adherence and persistence with branded antidepressants and generic SSRIs among managed care patients with major depressive disorder. Clinicoecon Outcomes Res. 2011;3:63\u201372.","journal-title":"Clinicoecon Outcomes Res"},{"key":"3793_CR13","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1080\/21556660.2019.1612410","volume":"8","author":"G Gauthier","year":"2019","unstructured":"Gauthier G, Mucha L, Shi S, Guerin A. Economic burden of relapse\/recurrence in patients with major depressive disorder. J Drug Assess. 2019;8:97\u2013103.","journal-title":"J Drug Assess"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-022-03793-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-022-03793-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-022-03793-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T04:04:12Z","timestamp":1646107452000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-022-03793-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,1]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["3793"],"URL":"https:\/\/doi.org\/10.1186\/s12888-022-03793-7","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,1]]},"assertion":[{"value":"20 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All methods were carried out in accordance with relevant guidelines and regulations. This study is exempt from Institutional Review Board requirements because it includes analyses of administrative claims datasets and fulfills the following exemption requirements: (1) the study does not include any individually identifiable health information, (2) the authors are authorized by the medical\/pharmacy database manager of Magellan Rx Management to use the Protected Health Information (PHI) in conducting analyses performed under the \u201cTreatment, Payment, Health Care Operations\u201d provision of Health Insurance Portability and Accountability Act of 1996 (HIPAA), and (3) the authors are bound to Magellan by confidentiality standards that protect individually identifiable health information, including HIPAA-compliant procedures for storage, transmission, release, and disposal of PHI.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"N\/A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"M.P. is an employee of Magellan Method, a Division of Magellan Rx Management, contracted by Takeda Pharmaceuticals U.S.A., Inc., and Lundbeck LLC to conduct the research for this study. A.K. was an employee of Magellan Method at the time of the study. L.C., T.E., and D.F.L. are employees of Takeda Pharmaceuticals U.S.A, Inc. M.T. is an employee of Lundbeck LLC.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"152"}}